

Ding-Wei Ye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5116182/publications.pdf>

Version: 2024-02-01

187
papers

4,107
citations

147566

31
h-index

189595

50
g-index

192
all docs

192
docs citations

192
times ranked

6397
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 379-387.	1.2	260
2	NADP+·-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. <i>Molecular Cell</i> , 2015, 60, 661-675.	4.5	175
3	Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. <i>Scientific Reports</i> , 2015, 5, 7654.	1.6	140
4	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	0.9	130
5	Identification and Validation of Stromal Immunity Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3069-3078.	3.2	124
6	Epidemiology and genomics of prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2021, 18, 282-301.	1.9	111
7	LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. <i>Cell Death and Disease</i> , 2021, 12, 1043.	2.7	89
8	Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. <i>Cancer Research</i> , 2019, 79, 2604-2618.	0.4	87
9	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
10	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e702-e708.	1.9	70
11	AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. <i>Developmental Cell</i> , 2019, 48, 345-360.e7.	3.1	66
12	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	1.7	62
13	Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 222-230.	2.9	61
14	Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. <i>Cancer Letters</i> , 2016, 380, 369-374.	3.2	60
15	The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10659.	3.3	56
16	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. <i>Nature Communications</i> , 2015, 6, 8469.	5.8	51
17	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
18	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. <i>Clinical Cancer Research</i> , 2020, 26, 4551-4558.	3.2	49

#	ARTICLE	IF	CITATIONS
19	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
20	A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. <i>Nature Communications</i> , 2022, 13, 2052.	5.8	48
21	Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. <i>World Journal of Surgical Oncology</i> , 2014, 12, 14.	0.8	47
22	Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3. <i>Cancer Research</i> , 2016, 76, 3277-3284.	0.4	46
23	SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 145.	3.5	43
24	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGF β 1/p-Smad2/3 signaling. <i>Cancer Letters</i> , 2020, 472, 151-164.	3.2	43
25	Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 5789-5799.	0.8	43
26	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. <i>Cancer Letters</i> , 2020, 485, 45-55.	3.2	42
27	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. <i>European Urology</i> , 2019, 76, 280-283.	0.9	41
28	Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. <i>Scientific Reports</i> , 2017, 7, 8869.	1.6	40
29	Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 605.e17-605.e23.	0.8	39
30	Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2015, 10, 3073-3080.	0.8	36
31	ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients. <i>Tumor Biology</i> , 2016, 37, 253-262.	0.8	34
32	circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762. <i>Oncology Letters</i> , 2019, 17, 3537-3547.	0.8	34
33	Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1435-1442.	0.7	33
34	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. <i>Oncolmmunology</i> , 2020, 9, 1762473.	2.1	33
35	Age-Dependent Association between Sex and Renal Cell Carcinoma Mortality: a Population-Based Analysis. <i>Scientific Reports</i> , 2015, 5, 9160.	1.6	32
36	Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series. <i>PLoS ONE</i> , 2015, 10, e0118022.	1.1	32

#	ARTICLE	IF	CITATIONS
37	A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. <i>Scientific Reports</i> , 2015, 5, 10905.	1.6	31
38	Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 950-961.	1.2	31
39	Identification and validation of an eight-gene expression signature for predicting high Fuhrman grade renal cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 1199-1208.	2.3	29
40	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. <i>Cancer</i> , 2019, 125, 1060-1069.	2.0	28
41	Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 23594.	1.6	27
42	A functional variant in <i>TP63</i> at 3q28 associated with bladder cancer risk by creating an miR-140-5p binding site. <i>International Journal of Cancer</i> , 2016, 139, 65-74.	2.3	27
43	Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data. <i>OncImmunology</i> , 2020, 9, 1784529.	2.1	27
44	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. <i>International Journal of Urology</i> , 2016, 23, 404-411.	0.5	26
45	Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population. <i>Scientific Reports</i> , 2016, 6, 21677.	1.6	26
46	Norcantharidin induces autophagy-related prostate cancer cell death through Beclin-1 upregulation by miR-129-5p suppression. <i>Tumor Biology</i> , 2016, 37, 15643-15648.	0.8	26
47	Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. <i>Prostate</i> , 2017, 77, 1221-1229.	1.3	26
48	Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 16, 866-874.	0.8	26
49	LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. <i>Cell Death and Disease</i> , 2020, 11, 638.	2.7	26
50	Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2015, 6, 27378-27387.	0.8	26
51	The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. <i>Scientific Reports</i> , 2017, 7, 9846.	1.6	25
52	Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. <i>European Urology Focus</i> , 2019, 5, 737-741.	1.6	25
53	Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. <i>Oncotarget</i> , 2017, 8, 71797-71804.	0.8	25
54	Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. <i>Journal of Urology</i> , 2020, 203, 562-569.	0.2	24

#	ARTICLE	IF	CITATIONS
55	Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 32723-32730.	0.8	24
56	A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. <i>Asian Journal of Urology</i> , 2017, 4, 75-85.	0.5	23
57	Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. <i>Oncotarget</i> , 2015, 6, 32212-32219.	0.8	23
58	Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 225-233.	0.9	22
59	SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 4564-4570.	0.8	22
60	ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. <i>Science Advances</i> , 2021, 7, .	4.7	22
61	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. <i>Scientific Reports</i> , 2017, 7, 2074.	1.6	21
62	Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5431-5438.	1.3	21
63	Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. <i>Oncotarget</i> , 2017, 8, 24362-24371.	0.8	21
64	CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15708-15.	1.3	21
65	Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men's Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	20
66	Causes of Death and Conditional Survival of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 591.	1.3	20
67	Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio. <i>Journal of Cancer</i> , 2019, 10, 249-256.	1.2	20
68	Expression of Dicer and Its Related MiRNAs in the Progression of Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0120159.	1.1	19
69	Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 152.	1.3	19
70	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	1.3	19
71	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	2.0	19
72	ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma. <i>Cancer Science</i> , 2015, 106, 687-691.	1.7	18

#	ARTICLE	IF	CITATIONS
73	Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1340-1346.	1.2	18
74	Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 610229.	1.6	18
75	A single nucleotide polymorphism in <i>ADIPOQ</i> predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. <i>Oncotarget</i> , 2015, 6, 32205-32211.	0.8	18
76	Comprehensive Analysis of <i>BAP1</i> Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms <i>in Silico</i> . <i>Journal of Cancer</i> , 2018, 9, 4108-4116.	1.2	17
77	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. <i>Oncologist</i> , 2020, 25, e1042-e1050.	1.9	17
78	Forkhead box series expression network is associated with outcome of clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 8669-8680.	0.8	16
79	Development and validation of lncRNAs-based nomogram for prediction of biochemical recurrence in prostate cancer by bioinformatics analysis. <i>Journal of Cancer</i> , 2019, 10, 2927-2934.	1.2	16
80	Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 856.	1.3	16
81	The Rare Variant rs35356162 in <i>UHRF1BP1</i> Increases Bladder Cancer Risk in Han Chinese Population. <i>Frontiers in Oncology</i> , 2020, 10, 134.	1.3	16
82	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. <i>Scientific Reports</i> , 2017, 7, 7587.	1.6	15
83	<i>B4GALT1</i> expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. <i>BMC Cancer</i> , 2018, 18, 590.	1.1	15
84	Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. <i>OncoTargets and Therapy</i> , 2015, 8, 1363.	1.0	14
85	Prognosis of Patients With Testicular Carcinoma Is Dependent on Metastatic Site. <i>Frontiers in Oncology</i> , 2019, 9, 1495.	1.3	14
86	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. <i>Nature Communications</i> , 2021, 12, 5779.	5.8	14
87	<i>NR1H3</i> Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Cancer</i> , 2017, 8, 852-860.	1.2	13
88	Expression of <i>ARID1B</i> Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3490-3497.	1.2	13
89	Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population. <i>Journal of Cancer</i> , 2018, 9, 923-928.	1.2	13
90	Multi-omics reveals novel prognostic implication of <i>SRC</i> protein expression in bladder cancer and its correlation with immunotherapy response. <i>Annals of Medicine</i> , 2021, 53, 596-610.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Annals of Translational Medicine</i> , 2015, 3, 279.	0.7	13
92	Systematic Genome-Wide Profiles Reveal Alternative Splicing Landscape and Implications of Splicing Regulator DExD-Box Helicase 21 in Aggressive Progression of Adrenocortical Carcinoma. <i>Phenomics</i> , 2021, 1, 243-256.	0.9	13
93	Comprehensive Multi-Omics Identification of Interferon- γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 734646.	2.2	13
94	Inherited Mutations in Chinese Men With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 54-62.	2.3	13
95	Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib. <i>Oncotarget</i> , 2016, 7, 26879-26887.	0.8	12
96	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. <i>Translational Andrology and Urology</i> , 2017, 6, 848-854.	0.6	12
97	Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 197-198.	2.0	12
98	Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. <i>BMC Cancer</i> , 2020, 20, 219.	1.1	12
99	<p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	0.9	12
100	PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway. <i>PLoS ONE</i> , 2017, 12, e0180862.	1.1	12
101	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 785410.	1.8	12
102	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 420-427.	2.6	12
103	Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. <i>Asian Journal of Andrology</i> , 2016, 18, 525.	0.8	11
104	Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 4523-4529.	0.8	11
105	Impact of Estrogen on the Relationship Between Obesity and Renal Cell Carcinoma Risk in Women. <i>EBioMedicine</i> , 2018, 34, 108-112.	2.7	11
106	Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China. <i>European Urology</i> , 2020, 78, 120-122.	0.9	11
107	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. <i>Cancers</i> , 2020, 12, 831.	1.7	11
108	High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 35244-35254.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. <i>BMC Medicine</i> , 2022, 20, 84.	2.3	11
110	NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 6121-6128.	0.8	10
111	Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 840-846.	0.5	10
112	Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. <i>Scientific Reports</i> , 2018, 8, 374.	1.6	10
113	m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709579.	1.3	10
114	Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?. <i>OncoTargets and Therapy</i> , 2014, 7, 2043.	1.0	9
115	TEX15L: A DNA repair gene associated with prostate cancer risk in Han Chinese. <i>Prostate</i> , 2017, 77, 1271-1278.	1.2	9
116	Relationship between PSA kinetics and Tc ^{99m} HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. <i>Prostate</i> , 2018, 78, 1215-1221.	1.2	9
117	Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study. <i>Frontiers in Oncology</i> , 2020, 10, 1521.	1.3	9
118	Complicated variation of simple renal cyst usually means malignancy: results from a cohort study. <i>World Journal of Surgical Oncology</i> , 2014, 12, 316.	0.8	8
119	Genetic variants in insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men. <i>OncoTargets and Therapy</i> , 2016, 9, 61.	1.0	8
120	Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. <i>Asian Journal of Urology</i> , 2019, 6, 114-121.	0.5	8
121	Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 89-99.	0.7	8
122	Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing. <i>Oncogene</i> , 2021, 40, 2382-2394.	2.6	8
123	ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754845.	1.3	8
124	Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772436.	1.8	8
125	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 12.	0.4	8
126	Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. <i>Cancer Medicine</i> , 2021, 10, 6697-6704.	1.3	7

#	ARTICLE	IF	CITATIONS
127	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 141-141.	0.8	7
128	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 511-520.	0.7	7
129	Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. World Journal of Surgical Oncology, 2015, 13, 172.	0.8	6
130	High CXCL12 chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncol Immunology, 2017, 6, e1359450.	2.1	6
131	Family history is significantly associated with prostate cancer and its early onset in Chinese population. Prostate, 2019, 79, 1762-1766.	1.2	6
132	Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node metastatic penoscrotal extramammary Paget's disease. Oncology Letters, 2019, 17, 2677-2686.	0.8	6
133	Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. International Urology and Nephrology, 2020, 52, 87-95.	0.6	6
134	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology, 2020, 10, 527952.	1.3	6
135	Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. International Journal of Urology, 2022, 29, 383-389.	0.5	6
136	Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 751977.	1.1	6
137	Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study. World Journal of Surgical Oncology, 2015, 13, 132.	0.8	5
138	Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer. World Journal of Urology, 2019, 37, 2165-2173.	1.2	5
139	Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy. Cancer Management and Research, 2020, Volume 12, 1779-1787.	0.9	5
140	RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 4518-4518.	0.8	5
141	Clinical significance of TMPRSS4 in prostate cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 8053-8.	0.5	5
142	Managing advanced prostate cancer in the Asia Pacific region: Real-world application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 686-695.	0.7	5
143	Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population. Molecular Carcinogenesis, 2015, 54, 632-641.	1.3	4
144	Genetic polymorphisms at 19q13.33 are associated with [p]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. Prostate, 2021, 81, 971-982.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab. <i>Medical Science Monitor</i> , 2019, 25, 6518-6522.	0.5	4
146	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
147	Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response. <i>International Journal of Cancer</i> , 2023, 152, 66-78.	2.3	4
148	Validation of the novel susceptibility loci for prostate cancer in a Chinese population. <i>Oncology Letters</i> , 2017, 15, 2567-2573.	0.8	3
149	PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 500-505.	0.7	3
150	Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy. <i>Tumori</i> , 2020, 106, 133-138.	0.6	3
151	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 3278-3286.	1.3	3
152	Development and validation of a mitochondrial metabolism-associated nomogram for prediction of prognosis in clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e120.	1.7	3
153	A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	3
154	Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2078-2083.	0.6	3
155	UriBLAD. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 61-70.	1.2	3
156	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	3
157	Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 514-514.	0.8	2
158	Survival after radical cystectomy for bladder cancer: Multicenter comparison between minimally invasive and open approaches. <i>Asian Journal of Urology</i> , 2020, 7, 291-300.	0.5	2
159	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4628-4628.	0.8	2
160	Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4573-4573.	0.8	2
161	Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib. <i>Aging</i> , 2019, 11, 11490-11503.	1.4	2
162	An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 303-303.	0.8	2

#	ARTICLE	IF	CITATIONS
163	A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 753920.	1.3	2
164	High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3400-3406.	1.2	1
165	Identification of a methylation panel aid in risk stratification in node- ϵ positive penile squamous cell carcinoma. <i>International Journal of Cancer</i> , 2021, 148, 1289-1298.	2.3	1
166	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	0.8	1
167	Adenylate cyclase-activating polypeptide 1 gene methylation predicts prognosis and the immune microenvironment of bladder cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e597.	1.7	1
168	Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4537-LBA4537.	0.8	1
169	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4595-TPS4595.	0.8	1
170	Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16588-e16588.	0.8	1
171	Genetic variants in telomere-maintenance genes and bladder cancer risk. <i>Chinese-German Journal of Clinical Oncology</i> , 2013, 12, 448-453.	0.1	0
172	Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib. <i>Future Oncology</i> , 2016, 12, 1783-1793.	1.1	0
173	Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. <i>Journal of Cancer</i> , 2018, 9, 3208-3215.	1.2	0
174	Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival. <i>Journal of Cancer</i> , 2019, 10, 4639-4646.	1.2	0
175	Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4537-LBA4537.	0.8	0
176	Correlation of blood eosinophil level with the clinical benefit of sorafenib in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15545-e15545.	0.8	0
177	A multicenter, noncontrolled clinical study of sorafenib adjuvant therapy in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15553-e15553.	0.8	0
178	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15591-e15591.	0.8	0
179	RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 560-560.	0.8	0
180	Identification and validation of an 8-gene expression signature for predicting high-Fuhrman grade renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 526-526.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.. Journal of Clinical Oncology, 2016, 34, 594-594.	0.8	0
182	Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.. Journal of Clinical Oncology, 2018, 36, TPS4605-TPS4605.	0.8	0
183	Prevalence of residual tumor in the prostate after contemporary systemic therapy.. Journal of Clinical Oncology, 2018, 36, e17001-e17001.	0.8	0
184	Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: Real-world data from a single Chinese center.. Journal of Clinical Oncology, 2019, 37, 570-570.	0.8	0
185	Germline DNA damage repair gene alterations in Chinese prostate patients: More than HRR and MMR.. Journal of Clinical Oncology, 2019, 37, e13041-e13041.	0.8	0
186	Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress.. Journal of Clinical Oncology, 2020, 38, TPS588-TPS588.	0.8	0
187	Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.02.010 . European Urology, 2022...	0.9	0